October 30, 2026 The post Avenzo Therapeutics to Present Preliminary Phase 1 Results from ORION-1 Study of AVZO-023, a Selective CDK4 Inhibitor, at the 2026 San Antonio Breast Cancer Symposium first appeared on Avenzo Therapeutics .
Need help?
Contact usOctober 30, 2026 The post Avenzo Therapeutics to Present Preliminary Phase 1 Results from ORION-1 Study of AVZO-023, a Selective CDK4 Inhibitor, at the 2026 San Antonio Breast Cancer Symposium first appeared on Avenzo Therapeutics .